Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule

Ana C. Calvo, María Moreno-Igoa, Renzo Mancuso, Raquel Manzano, Sara Olivn, María J. Mũoz, Clara Penas, Pilar Zaragoza, Xavier Navarro, Rosario Osta

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is one of the most devastating neurodegenerative diseases. Neurotrophic factors have been widely tested to counteract neurodegenerative conditions, despite their unspecific neuronal access. The non-toxic C-terminal fragment of the tetanus toxin (TTC) heavy chain has been studied not only as a carrier molecule to the CNS but also as a neuroprotective agent. Because the neurotrophic effects of BDNF have been demonstrated in vitro and in vivo, the question addressed in this work is whether a fusion molecule of BDNF-TTC may have a synergistic effect and enhance the neuroprotective properties of TTC alone in a mouse model of ALS. Methods. Recombinant plasmid constructs (pCMV-TTC and pCMV-BDNF-TTC) were injected into the quadriceps femoris and triceps brachialis muscles of SOD1G93A transgenic mice at 8 weeks of age. The hanging wire and rotarod tests were performed to assess motor coordination, strength and balance. Electrophysiological tests, morphological assays of spinal cord sections of L2 and L4 segments, and gene and protein expression analyses were performed. The Kaplan-Meier survival analysis test was used for comparisons of survival. Multiple comparisons of data were analyzed using a one-way analysis of variance (ANOVA). Results: Treatment with the fusion-molecule BDNF-TTC and with TTC alone significantly delayed the onset of symptoms and functional deficits of SOD1G93A mice. Muscle innervation was partially preserved with these treatments, and the number of surviving motoneurons in L2 spinal cord segment was increased particularly by the fusion protein induction. Inhibition of pro-apoptotic protein targets (caspase-3 and Bax) and significant phosphorylation of Akt and ERK were also found in the spinal cord of treated mice. Conclusions: Significant improvements in behavioral and electrophysiological results, motoneuron survival and anti-apoptotic/survival- activated pathways were observed with BDNF-TTC treatment. However, no synergistic effect was found for this fusion molecule. Although BDNF in the fusion molecule is capable of activating autocrine and neuroprotective pathways, TTC treatment alone yielded similar neuroprotection. Therefore, an accurate study of the neuroprotective effects of TTC fusion molecules should be performed to obtain a better understanding of its effects. © 2011 Calvo et al; licensee BioMed Central Ltd.
Original languageEnglish
Article number10
Pages (from-to)1-31
JournalOrphanet Journal of Rare Diseases
Volume6
Issue number1
DOIs
Publication statusPublished - 31 Mar 2011

Fingerprint Dive into the research topics of 'Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule'. Together they form a unique fingerprint.

Cite this